A total of 11% of RSV patients experienced a cardiac event, abnormal heart rhythm, heart failure, or ischemic heart disease.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
(CIDRAP News) The US Food and Drug Administration's (FDA's) Pediatric Advisory Committee voted today to recommend stronger label warnings for two antiviral influenza medicationsoseltamivir and zanamivirthat have been linked to reports of neuropsychiatric problems in children and teens, mainly in Japan.
Oseltamivir already carries a warning, but zanamivir currently carries no warning about reported neuropsychiatric effects.
(CIDRAP News) A World Health Organization (WHO) group that recently met to work out an agreement to ease the global sharing of H5N1 avian influenza viruses failed to resolve the issue, but signaled that work on the issues would continue.
Editor's Note: This article is one of an occasional series exploring the development of public health practices included in the CIDRAP Promising Practices: Pandemic Influenza Preparedness Tools online database. We hope that describing the process and context that drove development of these practices serves as a valuable tool for pandemic planning.
Editor's note: This article was originally published in CIDRAP News as a seven-part series running from October 25 through November 2, 2007. It investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Maryn McKennaContributing Writer
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Adults who are hospitalized with serious seasonal influenza infections are more likely to survive if they receive antiviral medications, and older patients may benefit even if treatment is delayed until more than 48 hours after their first symptoms, according to a new study by Canadian researchers.
(CIDRAP News) – The United States, Canada, and Mexico yesterday vowed to help each other during public health emergencies and outlined the types of aid they could provide and accept from each other in the event of a pandemic or other infectious disease outbreak.
Editor's note: This is the last in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.
(CIDRAP News) The federal government should step up efforts to prepare the nation's key infrastructure industries, such as energy and transportation, for an influenza pandemic, Congress's investigative agency said in a report this week.
Editor's note: This is the sixth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.
